Fibrosarcoma - Pipeline Review, H1 2018

  • ID: 4464913
  • Report
  • 83 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AntiCancer Inc
  • Cellestia Biotech AG
  • Elsalys Biotech SAS
  • Ignyta Inc
  • Intezyne Technologies Inc
  • Loxo Oncology Inc
  • MORE
Fibrosarcoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Pipeline Review, H1 2018, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape.

Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Fibrosarcoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fibrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 5 and 9 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Fibrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosarcoma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibrosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AntiCancer Inc
  • Cellestia Biotech AG
  • Elsalys Biotech SAS
  • Ignyta Inc
  • Intezyne Technologies Inc
  • Loxo Oncology Inc
  • MORE
Introduction

The Publisher's Report Coverage

Fibrosarcoma - Overview

Fibrosarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fibrosarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibrosarcoma - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

AntiCancer Inc

Cellestia Biotech AG

Elsalys Biotech SAS

Ignyta Inc

Intezyne Technologies Inc

Loxo Oncology Inc

Millennium Pharmaceuticals Inc

Novartis AG

Pharma Mar SA

PTC Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Fibrosarcoma - Drug Profiles

A-1R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AL-3818 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Inhibit Rho-GAP for Colon Cancer and Fibrosarcoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daunorubicin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSR-6434 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELB-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larotrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepacrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MI-130110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTC-596 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RT-11i - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapanisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEN-461 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibrosarcoma - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Fibrosarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Fibrosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2018

Fibrosarcoma - Pipeline by AntiCancer Inc, H1 2018

Fibrosarcoma - Pipeline by Cellestia Biotech AG, H1 2018

Fibrosarcoma - Pipeline by Elsalys Biotech SAS, H1 2018

Fibrosarcoma - Pipeline by Ignyta Inc, H1 2018

Fibrosarcoma - Pipeline by Intezyne Technologies Inc, H1 2018

Fibrosarcoma - Pipeline by Loxo Oncology Inc, H1 2018

Fibrosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Fibrosarcoma - Pipeline by Novartis AG, H1 2018

Fibrosarcoma - Pipeline by Pharma Mar SA, H1 2018

Fibrosarcoma - Pipeline by PTC Therapeutics Inc, H1 2018

Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Fibrosarcoma - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Fibrosarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advenchen Laboratories LLC
  • AntiCancer Inc
  • Cellestia Biotech AG
  • Elsalys Biotech SAS
  • Ignyta Inc
  • Intezyne Technologies Inc
  • Loxo Oncology Inc
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Pharma Mar SA
  • PTC Therapeutics Inc
  • Sumi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll